The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021 The Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer. Find out more Show/Hide
Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021 Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial. Find out more Show/Hide
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020 The Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider its decision not to recommend abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer. Find out more Show/Hide
Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer 26 Jun 2020
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy 28 Nov 2019
ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations 26 Jul 2019